Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma

Final analysis of the collaborative trial in relapsed aggressive lymphoma

Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, Devinder Singh Gill, David C. Linch, Marek Trneny, Andre Bosly, Noel J. Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Duḧrsen, Hans Hagberg, David D. Ma, Andreas Viardot, Ray Lowenthal, Josette Brier̀e, Gilles Salles, Craig Moskowitz, Bertram Glass

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Purpose: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods: In total, 477 patients with CD20 + DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results: After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P = .7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P < .05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). Conclusion: In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.

Original languageEnglish (US)
Pages (from-to)4462-4469
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number36
DOIs
StatePublished - Dec 20 2012
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Stem Cell Transplantation
Lymphoma
Disease-Free Survival
Therapeutics
Maintenance
Observation
Drug Therapy
Rituximab
Proportional Hazards Models
Survival Rate
Recurrence
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma : Final analysis of the collaborative trial in relapsed aggressive lymphoma. / Gisselbrecht, Christian; Schmitz, Norbert; Mounier, Nicolas; Gill, Devinder Singh; Linch, David C.; Trneny, Marek; Bosly, Andre; Milpied, Noel J.; Radford, John; Ketterer, Nicolas; Shpilberg, Ofer; Duḧrsen, Ulrich; Hagberg, Hans; Ma, David D.; Viardot, Andreas; Lowenthal, Ray; Brier̀e, Josette; Salles, Gilles; Moskowitz, Craig; Glass, Bertram.

In: Journal of Clinical Oncology, Vol. 30, No. 36, 20.12.2012, p. 4462-4469.

Research output: Contribution to journalArticle

Gisselbrecht, C, Schmitz, N, Mounier, N, Gill, DS, Linch, DC, Trneny, M, Bosly, A, Milpied, NJ, Radford, J, Ketterer, N, Shpilberg, O, Duḧrsen, U, Hagberg, H, Ma, DD, Viardot, A, Lowenthal, R, Brier̀e, J, Salles, G, Moskowitz, C & Glass, B 2012, 'Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma', Journal of Clinical Oncology, vol. 30, no. 36, pp. 4462-4469. https://doi.org/10.1200/JCO.2012.41.9416
Gisselbrecht, Christian ; Schmitz, Norbert ; Mounier, Nicolas ; Gill, Devinder Singh ; Linch, David C. ; Trneny, Marek ; Bosly, Andre ; Milpied, Noel J. ; Radford, John ; Ketterer, Nicolas ; Shpilberg, Ofer ; Duḧrsen, Ulrich ; Hagberg, Hans ; Ma, David D. ; Viardot, Andreas ; Lowenthal, Ray ; Brier̀e, Josette ; Salles, Gilles ; Moskowitz, Craig ; Glass, Bertram. / Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma : Final analysis of the collaborative trial in relapsed aggressive lymphoma. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 36. pp. 4462-4469.
@article{dc0c3fdec5b94c4c8cd0a84b6d740fb5,
title = "Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma",
abstract = "Purpose: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods: In total, 477 patients with CD20 + DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results: After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52{\%} and 53{\%} for the rituximab and observation groups, respectively (P = .7). Treatment with rituximab was associated with a 15{\%} attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P < .05), including relapsed disease within 12 months (EFS: 46{\%} v 56{\%} for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37{\%} v 61{\%} for saaIPI < 1), and prior treatment with rituximab (EFS: 47{\%} v 59{\%} for no prior rituximab). A significant difference in EFS between women (63{\%}) and men (46{\%}) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). Conclusion: In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.",
author = "Christian Gisselbrecht and Norbert Schmitz and Nicolas Mounier and Gill, {Devinder Singh} and Linch, {David C.} and Marek Trneny and Andre Bosly and Milpied, {Noel J.} and John Radford and Nicolas Ketterer and Ofer Shpilberg and Ulrich Duḧrsen and Hans Hagberg and Ma, {David D.} and Andreas Viardot and Ray Lowenthal and Josette Brier̀e and Gilles Salles and Craig Moskowitz and Bertram Glass",
year = "2012",
month = "12",
day = "20",
doi = "10.1200/JCO.2012.41.9416",
language = "English (US)",
volume = "30",
pages = "4462--4469",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma

T2 - Final analysis of the collaborative trial in relapsed aggressive lymphoma

AU - Gisselbrecht, Christian

AU - Schmitz, Norbert

AU - Mounier, Nicolas

AU - Gill, Devinder Singh

AU - Linch, David C.

AU - Trneny, Marek

AU - Bosly, Andre

AU - Milpied, Noel J.

AU - Radford, John

AU - Ketterer, Nicolas

AU - Shpilberg, Ofer

AU - Duḧrsen, Ulrich

AU - Hagberg, Hans

AU - Ma, David D.

AU - Viardot, Andreas

AU - Lowenthal, Ray

AU - Brier̀e, Josette

AU - Salles, Gilles

AU - Moskowitz, Craig

AU - Glass, Bertram

PY - 2012/12/20

Y1 - 2012/12/20

N2 - Purpose: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods: In total, 477 patients with CD20 + DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results: After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P = .7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P < .05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). Conclusion: In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.

AB - Purpose: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. Patients and Methods: In total, 477 patients with CD20 + DLBCL who were in their first relapse or refractory to initial therapy were randomly assigned to one of two salvage regimens. After three cycles of salvage chemotherapy, the responding patients received high-dose chemotherapy followed by ASCT. Then, 242 patients were randomly assigned to either rituximab every 2 months for 1 year or observation. Results: After ASCT, 122 patients received rituximab, and 120 patients were observed only. The median follow-up time was 44 months. The 4-year event-free survival (EFS) rates after ASCT were 52% and 53% for the rituximab and observation groups, respectively (P = .7). Treatment with rituximab was associated with a 15% attributable risk of serious adverse events after day 100, with more deaths (six deaths v three deaths in the observation arm). Several factors affected EFS after ASCT (P < .05), including relapsed disease within 12 months (EFS: 46% v 56% for relapsed disease after 12 months), secondary age-adjusted International Prognostic Index (saaIPI) more than 1 (EFS: 37% v 61% for saaIPI < 1), and prior treatment with rituximab (EFS: 47% v 59% for no prior rituximab). A significant difference in EFS between women (63%) and men (46%) was also observed in the rituximab group. In the Cox model for maintenance, the saaIPI was a significant prognostic factor (P < .001), as was male sex (P = .01). Conclusion: In relapsed DLBCL, we observed no difference between the control group and the rituximab maintenance group and do not recommend rituximab after ASCT.

UR - http://www.scopus.com/inward/record.url?scp=84871731101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871731101&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.41.9416

DO - 10.1200/JCO.2012.41.9416

M3 - Article

VL - 30

SP - 4462

EP - 4469

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -